Cited 0 times in
MARIPOSA-2: Randomized phase III study of amivantamab plus lazertinib plus chemotherapy vs chemotherapy alone in EGFRmutant NSCLC after osimertinib failure
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.